Immunome profiling in prostate cancer: a guide for clinicians.

Area of Science:

• Oncology
• Immunology
• Genitourinary Cancer Research

Background:

• The tumor immune microenvironment (TIME) is critical for understanding prostate cancer (PC) treatment efficacy and resistance mechanisms.
• Genomic alterations like microsatellite instability (MSI) and CDK12 loss may predict response to immune checkpoint inhibitors (ICI) in PC.
• Treatment responses to immunotherapies in PC patients remain variable, necessitating deeper insights into immune cell dynamics.

Purpose of the Study:

• To analyze the role of immune cell and tumor stroma interactions in modulating PC progression.
• To investigate how standard PC therapies (ADT, hormone therapy, chemotherapy) impact the immunome.
• To identify limitations in characterizing the host's immune response within the tumor microenvironment.

Main Methods:

• Review of existing literature on prostate cancer immunology and therapy.
• Analysis of interactions between immune cells, stromal cells, and tumor cells.
• Examination of the impact of established PC treatments on the tumor immune landscape.

Main Results:

• Immune cell populations and their interactions within the tumor stroma significantly influence PC progression.
• Standard PC therapies can induce dynamic changes in the tumor immunome, affecting treatment outcomes.
• Current methods for characterizing the host immune response in PC tumors have notable limitations.

Conclusions:

• A comprehensive understanding of the TIME, including cellular interactions and therapy-induced changes, is essential for improving PC treatment strategies.
• Further research is needed to overcome limitations in assessing the immune landscape for better patient stratification and therapeutic development.
• Elucidating the plasticity and interactions of tumor-infiltrating immune cells can unlock novel therapeutic avenues for prostate cancer.